UK’s health and social care watchdog has decided against recommending Mounjaro, Eli Lilly’s weight loss drug for adults with diabetes.
The National Institute for Health and Care Excellence (NICE) in the UK released draft guidance stating that they need more information about tirzepatide, the active ingredient in Mounjaro.
“Our committee can see the promise in tirzepatide, but it requires more evidence to be able to evaluate both its clinical and cost-effectiveness,” said Helen Knight, director of medicines evaluation at NICE.
NICE provides national guidance and evaluates the cost-effectiveness of medications. As a nondepartmental public body, it operates under the sponsorship of the Department of Health and Social Care….